BioCardia (BCDA)
(Real Time Quote from BATS)
$1.71 USD
-0.10 (-5.53%)
Updated Aug 6, 2025 12:48 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCDA 1.71 -0.10(-5.53%)
Will BCDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCDA
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
BCDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
MiMedx (MDXG) Q3 Earnings and Revenues Surpass Estimates
Other News for BCDA
BioCardia (BCDA) Eyes Regulatory Approvals for Key Cardiovascular Innovations
BioCardia provides update on plan seeking approval for CardiAMP and Helix
BioCardia (BCDA) Advances CardiAMP Cell Therapy in Japan | BCDA Stock News